Pooling data from three longitudinal cohorts, daily cannabis use before age 17 was associated with a 63% lower chance of finishing high school, an 18-fold increase in cannabis dependence, and a 7-fold increase in suicide attempts — after controlling for 53 confounders.
Parents, educators, policymakers, and teenagers themselves. Also relevant for young adults processing the consequences of early cannabis use.
63% lower odds of high school completion for daily users before age 17
The Backstory
Most cannabis-cognition studies measure what happens in the brain. This one measured what happens in life.
Edmund Silins and the Cannabis Cohorts Research Consortium pooled data from three long-running longitudinal studies spanning Australia and New Zealand — thousands of adolescents followed from their teenage years into their thirties — and asked a question that mattered more to families than any brain scan: does teenage cannabis use predict worse life outcomes?
The answer came back as a dose-response curve with numbers that stopped parents mid-sentence.
Three Cohorts, One Analysis
This wasn't a single study. It was a meta-individual analysis — integrating raw, participant-level data from three of the most rigorous longitudinal cohorts in the Southern Hemisphere.
Process
The Three Cohorts
Australian Temperament Project
2,443 infants enrolled in 1983 from a representative sample of Victorian (Australia) families. Followed through age 30 with 15 assessment waves.
Christchurch Health and Development Study
1,265 children born in Christchurch, New Zealand, in 1977. Assessed at birth and ages 4 months, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 15, 16, 18, 21, 25, and 30 years.
Victorian Adolescent Health Cohort Study
1,943 students from schools across Victoria, Australia, recruited at ages 14-15. Followed through age 29 with 10 assessment waves.
Integrated analysis
Individual participant data pooled across all three cohorts. Sample sizes ranged from 2,537 to 3,765 depending on the outcome. Cannabis use assessed as maximum frequency before age 17: never, less than monthly, monthly or more, weekly or more, or daily.
Silins et al. (2014), Lancet Psychiatry 1(4):286-93
The design's power came from its depth of confound control. The analysis adjusted for up to 53 covariates — including other drug use, family dysfunction, mental health, socioeconomic status, parental education, and childhood behavioral problems. The goal was to strip away everything that might independently predict both cannabis use and poor outcomes, leaving only the association between cannabis itself and what happened next.
What They Found
Seven outcomes. Every one showed a dose-response relationship with adolescent cannabis frequency.
Life Outcomes
Daily Cannabis Use Before Age 17 vs. Never-Users
63% lower
High school completion
aOR 0.37 (0.20-0.66)
62% lower
University degree
aOR 0.38 (0.22-0.66)
18x higher
Cannabis dependence
aOR 17.95 (9.44-34.12)
8x higher
Other illicit drug use
aOR 7.80 (4.46-13.63)
7x higher
Suicide attempt
aOR 6.83 (2.04-22.90)
Elevated
Depression and welfare dependence
consistent dose-response associations
Silins et al. (2014), Lancet Psychiatry
The numbers were stark for daily users. But the dose-response pattern — more cannabis, worse outcomes, in a graded fashion — was what gave the findings their weight. Less-than-monthly users showed small or non-significant associations. Monthly users showed intermediate effects. Weekly users showed clear effects. Daily users showed dramatic effects. That gradient is what you'd expect if the relationship were at least partly causal, not just a product of shared risk factors.
The 53 Covariates
The most common criticism of observational cannabis studies is confounding: kids who use cannabis daily also tend to have other risk factors (family instability, mental health problems, poverty, other substance use) that independently predict poor outcomes. Maybe cannabis is just a marker for a troubled life, not a cause of the trouble.
Silins addressed this more thoroughly than almost any prior study. The 53 covariates included:
Confound Control
What the Analysis Controlled For
Demographics
Age, sex, ethnicity, socioeconomic status, parental education, family structure
Mental health
Baseline depression, anxiety, conduct disorder, childhood behavioral problems
Other substances
Tobacco use, alcohol use, other illicit drug use — all assessed independently
Family factors
Parental substance use, family dysfunction, family conflict, parent-child attachment
What survived
The dose-response associations between cannabis frequency and all seven outcomes persisted after adjusting for all 53 covariates
Silins et al. (2014), Lancet Psychiatry
After all 53 adjustments, the associations remained. Daily cannabis use before age 17 still predicted a 63% reduction in odds of completing high school. The confounders didn't explain it away.
But "not explained by 53 covariates" is not the same as "causal." There could be unmeasured confounders. The relationship might be partially causal and partially driven by shared vulnerability factors — which is what most researchers now believe.
Why This Study Matters
The Silins study moved the conversation from "does cannabis affect brain scans?" to "does cannabis affect lives?" Brain imaging studies like Albaugh's cortical thinning work show structural changes. Cognitive studies like Scott's meta-analysis show test score differences. But this study showed outcomes that every parent, teacher, and teenager can understand: diplomas, degrees, dependence, and despair.
The multi-cohort design made it especially hard to dismiss. If the same pattern appears independently in three different samples from two different countries, it's unlikely to be a quirk of one dataset.
The timing of the Silins publication — September 2014 — was significant. It landed in the same year as Volkow's NEJM review of cannabis adverse effects and just two years after the Meier Dunedin IQ study. Together, these three papers formed the evidence base that shifted the scientific consensus: adolescent cannabis use carries real, measurable risks to development and life outcomes, distinct from the risks of adult use. Within a year, every major medical organization had updated its position on adolescent cannabis exposure.
For parents navigating conversations about cannabis with their teenagers, this study provides something rare: numbers that connect directly to life outcomes rather than abstract neuroscience. Not "your prefrontal cortex is thinning" — but "daily use before 17 means you're less than half as likely to finish high school." That message lands differently in a conversation with a 15-year-old.
And for young adults who used heavily as teenagers and are now dealing with educational setbacks, the study is honest about the risk while the broader literature is honest about recovery. Cognitive function recovers. Brain chemistry normalizes. Educational pathways remain open. The dose-response works in both directions: stopping or reducing use is associated with improved trajectories.
Young adult sequelae of adolescent cannabis use: an integrative analysis
Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP; Cannabis Cohorts Research Consortium (2014) · The Lancet Psychiatry
Does this prove cannabis causes these outcomes?
It's among the strongest observational evidence available, controlling for 53 potential confounders across three independent cohorts. But observational studies cannot definitively prove causation. The relationship is likely partly causal and partly driven by shared risk factors. What's clear is that the association persists even after extensive confound control and follows a dose-response pattern — both hallmarks of likely causation.
What about occasional teenage use?
The study showed a dose-response: less-than-monthly users had small or non-significant associations with adverse outcomes. The dramatic effects (60%+ reductions in school completion) were concentrated in daily users. Occasional, experimental use before age 17 carried much less risk than daily use — though it still conferred elevated odds of later cannabis dependence.
If I used daily as a teen, am I doomed?
No. The study reports group-level averages, not individual destinies. Many daily adolescent users completed high school, earned degrees, and avoided dependence. The odds are worse, not zero. And other evidence shows that cognitive function recovers with abstinence and that brain chemistry normalizes. Educational pathways remain open at any age.
Why does age matter so much?
The adolescent brain is still developing — particularly the prefrontal cortex, which governs planning, impulse control, and decision-making. Cannabis disrupts this development in ways that adult brains, which have completed maturation, are more resilient to. The Silins findings are specific to use before age 17, during the most active period of prefrontal development.
What the researchers found
Daily cannabis use before age 17 significantly reduced odds of high school completion (aOR 0.37) and degree attainment (aOR 0.38), while increasing odds of cannabis dependence (aOR 17.95), other illicit drug use (aOR 7.80), and suicide attempt (aOR 6.83). Clear dose-response patterns persisted after adjusting for 53 covariates across three independent cohorts.
Why it matters
Translates brain science into life outcomes. Multi-cohort design with 53 covariates provides among the strongest observational evidence that adolescent cannabis use predicts worse educational, substance, and mental health outcomes in adulthood.
How the study worked
Meta-individual analysis integrating participant-level data from three longitudinal Australasian cohorts (Australian Temperament Project, Christchurch Health and Development Study, Victorian Adolescent Health Cohort Study). Cannabis frequency before age 17 categorized as never/less than monthly/monthly+/weekly+/daily. Seven outcomes assessed to age 30. Adjusted for up to 53 covariates.
What this study cannot tell us
Observational design cannot prove causation despite extensive confound control. Unmeasured confounders possible. All three cohorts from Australia/NZ — may not generalize to other populations. Self-report cannabis measures. Cannot separate cannabis effects from correlated lifestyle factors entirely.
How to read the evidence
Strong observational evidence: multi-cohort meta-individual design with extensive confound control (53 covariates), dose-response patterns, and consistency across three independent samples. Cannot establish causation definitively.
The bigger picture
Part of the 2012-2014 evidence wave (alongside Meier Dunedin IQ study and Volkow NEJM review) that shifted scientific consensus on adolescent cannabis risk and informed age-based policy recommendations.
Read the original research
Young adult sequelae of adolescent cannabis use: an integrative analysis.
The Lancet. Psychiatry, 1(4), 286-93
Citation
Silins, Edmund; Horwood, L John; Patton, George C; Fergusson, David M; Olsson, Craig A; Hutchinson, Delyse M; Spry, Elizabeth; Toumbourou, John W; Degenhardt, Louisa; Swift, Wendy; Coffey, Carolyn; Tait, Robert J; Letcher, Primrose; Copeland, Jan; Mattick, Richard P. (2014). Young adult sequelae of adolescent cannabis use: an integrative analysis.. The Lancet. Psychiatry, 1(4), 286-93. https://doi.org/10.1016/S2215-0366(14)70307-4